

# Press Release

Abliva AB (publ), 556595-6538  
16 September 2021 13:35:00 CEST - Lund,  
Sweden



---

## Meet Abliva's CEO live: Fireside Chat in Stockholm and Lund

**Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases (PMD), would like to invite interested shareholders and investors to a fun and informal "Fireside Chat" with the company's CEO, Ellen Donnelly, and members of the Abliva team, in Stockholm (28 September) and Lund (29 September).**

After a long stretch of stringent travel restrictions and two-dimensional zoom presentations, we would like to invite Abliva shareholders and interested investors to an informal gathering to hear more about the Abliva strategy and direction directly from Ellen Donnelly (CEO) and the Abliva team. Ellen, an American, joined the company as CEO in February 2021 but has been unable to visit due to COVID restrictions. We hope you will join us in Stockholm or Lund at the end of the month to hear an update on the company and ask your most pressing questions. Seats are limited so please respond quickly to reserve your space.

Stockholm (center): 28 September, 5:00 - 6:00 p.m. CEST.

Lund: 29 September, 4:30 - 5.30 p.m. CEST.

Please respond to [anmalan@abliva.com](mailto:anmalan@abliva.com) to reserve your space. Meeting details will be provided after registration.

**For more information, please contact:**

---

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations  
+46 (0)46-275 62 21, [ir@abliva.com](mailto:ir@abliva.com)

### **Abliva AB (publ)**

Medicon Village, SE-223 81 Lund, Sweden

Tel: +46 (0)46 275 62 20 (switchboard)

[info@abliva.com](mailto:info@abliva.com), [www.abliva.com](http://www.abliva.com)

Subscribe to our news: <https://abliva.com/posts/news-subscription/>

Follow us on LinkedIn: <https://www.linkedin.com/company/abliva>

Subscribe to our YouTube channel: <https://www.youtube.com/channel/UCChqP7Ky5caXtp72CELhD6Mg>

# Press Release

Abliva AB (publ), 556595-6538  
16 September 2021 13:35:00 CEST - Lund,  
Sweden



---

## **Abliva – Delivering mitochondrial health**

---

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD<sup>+</sup> regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, is in preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

## **Attachments**

---

[Meet Abliva's CEO live: Fireside Chat in Stockholm and Lund](#)